Xiaofan Wu1, Shuzheng Lv1, Xiaohong Yu2, Linyin Yao3, Babak Mokhlesi2, Yongxiang Wei4. 1. Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. 2. Department of Medicine, Section of Pulmonary and Critical Care, Sleep Disorders Center, University of Chicago, Chicago, IL. 3. Department of Otolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. 4. Department of Otolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: drwuxf@163.com.
Abstract
BACKGROUND: The impact of OSA treatment with CPAP on percutaneous coronary intervention (PCI) outcomes remains largely unknown. METHODS: Between 2002 and 2012, we identified 390 patients with OSA who had undergone PCI. OSA was diagnosed through in-laboratory sleep studies and defined by an apnea-hypopnea index ≥ 5 events/h. The cohort was divided into three groups: (1) moderate-severe OSA successfully treated with CPAP (n = 128), (2) untreated moderate-severe OSA (n = 167), and (3) untreated mild OSA (n = 95). Main outcomes included repeat revascularization, major adverse cardiac events (MACEs) (ie, death, nonfatal myocardial infarction, repeat revascularization), and major adverse cardiac or cerebrovascular events (MACCEs). The median follow-up period was 4.8 years (interquartile range, 3.0-7.1). RESULTS: The untreated moderate-severe OSA group had a higher incidence of repeat revascularization than the treated moderate-severe OSA group (25.1% vs 14.1%, P = .019). There were no differences in mortality (P = .64), MACE (P = .33), and MACCE (P = .76) among the groups. In multivariate analysis adjusted for potential confounders, untreated moderate-severe OSA was associated with increased risk of repeat revascularization (hazard ratio, 2.13; 95% CI, 1.19-3.81; P = .011). CONCLUSIONS: Untreated moderate-severe OSA was independently associated with a significant increased risk of repeat revascularization after PCI. CPAP treatment reduced this risk.
BACKGROUND: The impact of OSA treatment with CPAP on percutaneous coronary intervention (PCI) outcomes remains largely unknown. METHODS: Between 2002 and 2012, we identified 390 patients with OSA who had undergone PCI. OSA was diagnosed through in-laboratory sleep studies and defined by an apnea-hypopnea index ≥ 5 events/h. The cohort was divided into three groups: (1) moderate-severe OSA successfully treated with CPAP (n = 128), (2) untreated moderate-severe OSA (n = 167), and (3) untreated mild OSA (n = 95). Main outcomes included repeat revascularization, major adverse cardiac events (MACEs) (ie, death, nonfatal myocardial infarction, repeat revascularization), and major adverse cardiac or cerebrovascular events (MACCEs). The median follow-up period was 4.8 years (interquartile range, 3.0-7.1). RESULTS: The untreated moderate-severe OSA group had a higher incidence of repeat revascularization than the treated moderate-severe OSA group (25.1% vs 14.1%, P = .019). There were no differences in mortality (P = .64), MACE (P = .33), and MACCE (P = .76) among the groups. In multivariate analysis adjusted for potential confounders, untreated moderate-severe OSA was associated with increased risk of repeat revascularization (hazard ratio, 2.13; 95% CI, 1.19-3.81; P = .011). CONCLUSIONS: Untreated moderate-severe OSA was independently associated with a significant increased risk of repeat revascularization after PCI. CPAP treatment reduced this risk.
Authors: Apoor S Gami; Gregg Pressman; Sean M Caples; Ravi Kanagala; Joseph J Gard; Diane E Davison; Joseph F Malouf; Naser M Ammash; Paul A Friedman; Virend K Somers Journal: Circulation Date: 2004-07-12 Impact factor: 29.690
Authors: Luciano F Drager; Luiz A Bortolotto; Adelaide C Figueiredo; Eduardo M Krieger; Geraldo Filho Lorenzi Journal: Am J Respir Crit Care Med Date: 2007-06-07 Impact factor: 21.405
Authors: Shahrokh Javaheri; Ferran Barbe; Francisco Campos-Rodriguez; Jerome A Dempsey; Rami Khayat; Sogol Javaheri; Atul Malhotra; Miguel A Martinez-Garcia; Reena Mehra; Allan I Pack; Vsevolod Y Polotsky; Susan Redline; Virend K Somers Journal: J Am Coll Cardiol Date: 2017-02-21 Impact factor: 24.094
Authors: R Nisha Aurora; Ciprian Crainiceanu; Daniel J Gottlieb; Ji Soo Kim; Naresh M Punjabi Journal: Am J Respir Crit Care Med Date: 2018-03-01 Impact factor: 21.405
Authors: Michał Hoffmann; Jacek Wolf; Anna Szyndler; Prachi Singh; Virend K Somers; Krzysztof Narkiewicz Journal: Arch Med Sci Date: 2015-12-16 Impact factor: 3.318